Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy

NCT01751776 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

107

Enrollment

INDUSTRY

Sponsor class

Conditions

Arthritis, Rheumatoid
Healthy

Interventions

DRUG: Placebo matching BI 655064
DRUG: BI 655064

Sponsor

Boehringer Ingelheim